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Interferon g-induced protein 10 kDa (IP-10) is a potent chemoattractant and has been suggested to
enhance antitumor activity and mediate tumor regression through multiple mechanisms of action.
Multiple lines of evidence have indicated that genetically-modiﬁed adult stem cells represent a potential
source for cell-based cancer therapy. In the current study, we assessed therapeutic potential of human
adipose derived mesenchymal stem cells (hADSC) genetically-modiﬁed to express IP-10 for the treat-
ment of lung metastasis in an immunocompetent mouse model of metastatic melanoma. A Piggybac
vector encoding IP-10 was employed to transfect hADSC ex vivo. Expression and bioactivity of the
transgenic protein from hADSCs expressing IP-10 were conﬁrmed prior to in vivo studies. Our results
indicated that hADSCs expressing IP-10 could inhibit the growth of B16F10 melanoma cells and signif-
icantly prolonged survival. Immunohistochemistry analysis, TUNEL assay and western blot analysis
indicated that hADSCs expressing IP-10 inhibited tumor cell growth, hindered tumor inﬁltration of Tregs,
restricted angiogenesis and signiﬁcantly prolonged survival. In conclusion, our results demonstrated that
targeting metastatic tumor sites by hADSC expressing IP-10 could reduce melanoma tumor growth and
lung metastasis.
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Melanoma is known as a metastatic and aggressive type of
cancer that in most cases is diagnosed in the late stages [1]. It has
been shown that melanoma cells have preferential metastasis to
the lung, brain, skin, and liver tissues [2,3]. Therefore, ﬁnding a new
effective treatment for patients with metastatic melanoma is
necessary.
CXCL10 (also known as interferon-inducible protein (IP-10)) is
an important CXC chemokine which possesses various anti-cancer
effects [4,5]. IP-10 shows anti-angiogenic and apoptotic effects on
various cancer cells [5]. It has been shown that this chemokine
could contribute to the generation and trafﬁcking of activated T
cells to the inﬂammation and tumor sites and improve immune
system against tumor cells [6e8]. Hence, it seems that IP-10 could
be used as a therapeutic option for the treatment of various types of
cancer including melanoma. Several studies have employed
immunotherapy-based approaches against different targets for the
treatment of patients withmelanoma [9,10]. However, utilization of
these approaches is associated with some limitations and adverse
effects. Hence, speciﬁc targeting of immunomodulatory factors
such as cytokines and chemokines could overcome these limita-
tions [9,10].
Multiple lines of evidence have indicated that mesenchymal
stem cells (MSCs) could migrate to tumor sites via expressing
various receptors (e.g. CCR1, CCR2, CCR5, CCR6 and CXCR1), growth
factors (e.g. TGF-b1, PGF, and HGF) and other proteins (antigen 4,
and vascular cell adhesion molecule-1) [11]. Therefore, these cells
could be applied as a cellular vehicle for carrying various thera-
peutic agents [12e15]. Adipose tissue is one of the important sites
for the isolation of MSCs [16]. Several studies have conﬁrmed that
ADSCs could be an efﬁcient vehicle for the delivery of different
therapeutic agents to tumor sites [15,16].
In the current study, we assessed the therapeutic effect of hu-
man adipose-derivedmesenchymal stem cells (hADSCs) expressing
IP-10 in a melanoma lung metastasis model.
2. Material and methods
2.1. Isolation of hADSCs and culture
Human adipose tissues were provided from lipoaspirate sam-
ples of abdominal fat from male donors (age range 20e30 years)
and after obtaining informed consent and were split as previously
described [17]. At ﬁrst, to remove contaminating debris and red
blood cells of adipose tissue samples, they were washed with
phosphate-buffer saline (PBS). Samples were treated with 0.075%
collagenase type I in PBS for 30min at 37 C. For neutralization of
enzyme activity were added an equal volume of Dulbecco's modi-
ﬁed eagles medium (DMEM/F12) (Gibco BRL, Paisley, UK) contain-
ing 10% fetal bovine serum (FBS). The reached infranatant was
centrifuged for 10min at 1,2009g and cellular pellet was re-
suspended in speciﬁc media (DMEM/F12, 10% FBS, and 1% peni-
cillin/streptomycin). These cells were split in 25 cm2 ﬂasks for 4e5
days in a 37 C humidiﬁed incubator with a 5% CO2 environment to
provided good conﬂuency (80%) (These cells deﬁned as passage 0).
At good conﬂuency, cells were split with 0.25% Trypsin/0.02% EDTA
at the ratio of 1:3 in every passage. Moreover, all procedures were
approved by the Ethics Committee of Mashhad University of
Medical Sciences.
2.2. Immunotyping of ADSCs
Immunotyping of ADSCs was performed by ﬂow cytometry on a
FACscan ﬂow cytometry in our previous study (BectoneDickinson,San Jose, CA). Brieﬂy, a total of 5 105 human ADSCs (within 3
passages) were provided by trypsinization, and washed with 1%
BSA/PBS. At other step, the reached cells were incubated with an-
tibodies against human CD90, CD44, CD14, and CD45 (Chemicon,
Temecula, CA, USA) for 30min at 4 C. Analysis of the FACS datawas
carried out with a FlowJo software version 10 (Treestar, OR).
2.3. Plasmid construction
Plasmid pCMV-hyPBase was obtained from the Wellcome Trust
Sanger Institute (Hinxton, Cambridge, UK). The coding sequence of
Piggybac transposase was ampliﬁed by Pfu polymerase using 50-
ATATACGCGTTGACATTGATTATTGACTAG-30 and 50-ATTGCTAG-
CAGCTGGTTCTTTCCGCCTC-30 as forward and reverse primers,
respectively. Then it was cloned into Mlul and Nhel restriction sites
of pPIG- IP-10 (CXCL10). Synthesized pPIG- IP-10 plasmid is
composed of coding sequence of mouse IP-10 and hygromycin
resistance genes separated by 2A peptide sequence. Theses coding
sequences are ﬂanked by terminal repeat element (TRE) sequence
of Piggybac (Fig. 1A).
We used other Piggybac vectors including pT-tdTomato, pT-neo
and pTrans For transfection of B16f10 cell lines (kindly provided by
Dr. Masahiro Sato) (Fig.1 B). These vectors were created by standard
cloning procedures. Brieﬂy, the pPB vector consists of two PB ac-
ceptors with inverted repeats. pT-neo (formerly referred to as
pTpB) is a pPB-based vector which is consisted of a neomycin
resistance gene (neo) expression unit (CMV
promoterþ neoþ poly(A) sites). pT-tdTomato is a pPB-based vector
which is consisted of a tandem dimer Tomato (tdTomato) cDNA
expression unit under the control of the CAG promoter. Moreover,
the pTrans vector expresses transposase under the CAG promoter
[18].
2.4. Human ADSCs transfection, selection, and transgene expression
ADSCs cells were transfected by the Lipofectamine 2000 trans-
fection reagent (Invitrogen, CA, USA). 5 106 ADSCs were plated in
a 6-well plate to obtain a conﬂuency of 80% after 24 h. Transfection
efﬁciency was assessed using a helper-independent plasmid. Forty-
eight hours after transfection, cells were treated with 150 mg/mL of
hygromycin B (Roche) to allow the growth of stable clones for at
least 14 days.
2.5. Cancer cell culture, transfection, and selection
The B16F10 cell line was purchased from the Pasteur Institute of
Iran (https://www.pasteur.fr/en). Cancer cells were maintained in
cellular medium at 37 C in a 5% CO2 atmosphere. In the present
study, B16F10 was transfected with pT-tdTomato, pT-neo and
pTrans to provide RFP-melanoma cells respectively (Fig. 2). Lip-
ofection was used for modiﬁcation of melanoma cells. Brieﬂy, to
provide transgenic B16F10 cells, a density of 2 105 cells per well in
triplicate for each group was seeded in 6-well plates. After 24 h,
cells were co-transfected with the vector pT-tdTomato, pT-neo and
pTrans using lipofectamine 2000™ transfection reagent (Invi-
trogen, Carlsbad, CA) according to the manufacturer's instructions.
We checked transfection cells 24 h, 48 h and 72 h after transfection.
Melanoma cells were selected, and maintained with 1000 mg/mL of
G418. RFP melanoma was exposed to 400 mg/mL neomycin (Invi-
trogen, Carlsbad, CA) for about two weeks.
2.6. Reverse-transcriptase polymerase chain reaction (RT-PCR)
To conﬁrm the up-regulation of IP-10 gene expression in
hADSCs, total RNAs were isolated from the hADSCs and reverse
Fig. 1. Schematic presentation of the used vectors for transfection of hADSCs and B16F10. Here brieﬂy describe what is shown in the ﬁgure. The plasmid backbone is not shown in
the ﬁgure. A) Piggybac containing IP-10 and EGFP. ITR: Inverted Terminal Repeat; IP-10: Interferon gamma-induced protein 10; Hyg R: Hygromycin resistance; CMV: cytomega-
lovirus. B) Depiction of the expression vectors used for transfection of melanoma cells. The plasmid backbone is not shown in the ﬁgure. CAG: cytomegalovirus enhancer 1 chicken
b-actin promoter; pA: poly (A) sites; neo: neomycin resistance gene; PB: acceptor site in the PiggyBac system; PGKp: mouse phosphoglycerate kinase promoter; tdTomato: tandem
dimer Tomato cDNA; Transposase: PB transposase gene.
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(64). The PCR primer sequences targeting murine IP-10 were for-
ward 50-CGGAATTCATCAGCACCATGAACCCAAGT-30, and revers 50-
GCGTGGCTT CTCTCCAGTT-30, and GAPDH forward 50-CTGCACCAC-
CAACTGCTTAG-30) and revers 50- GTCTGGGARGGAAARRGRGA-3'.2.7. Western blot on cultured cells
To analyze the expression of IP-10 in hADSCs, Piggybac-IP-10
(PB-IP-10) was transfected by Lipofectamine 2000 to hADSCs in
culture. After 48 h, all groups of hADSCs were lysed in lysis buffer
(10mM Tris-Cl, pH 7.4, 0.15M NaCl, 5mM EDTA, and 1% Triton X-
100) containing 100 g/mL protease inhibitors (Sigma-Aldrich, St.
Louis, http://www.sigmaaldrich.com). The content of IP-10 was
determined using the Bio-Rad Dc protein assay kit (Bio-Rad, Mis-
sissauga, ON, Canada). Ten micrograms of total protein from each
sample was separated by 10% SDS-polyacrylamide gel electropho-
resis and trans-blotted onto polyvinylidene diﬂuoride membrane.
The membranes were blocked in blocking buffer (5% powdered
non-fat milk in PBS) containing 0.05% Tween-20. The blot was
probed with a polyclonal rabbit anti-mouse IP-10 antibody at
1:1000 (catalog no. ab9938; Abcam, Cambridge, MA) followed bybinding with an anti-rabbit secondary antibody at 1:11000 dilution
(catalog no. ab37168; Abcam, Cambridge, MA). IP-10 protein and
GADH (control) bands was identiﬁed using chemiluminescence kit
(Amersham Biosciences/GE Healthcare, Little Chalfont, U.K.,).2.8. Cell proliferation assay
Melanoma cells were seeded in 96-well plates at a density of
7.5 103 cells per well and incubated at 37 C for 24 h. Superna-
tants frommock and IP-10 plasmid transfected hADSCs were added
to the plate and returned to the incubator for 3 days. We deter-
mined IP-10 concentration using ELISA at about 2.4 ng/mL of su-
pernatant. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) dyewas added to eachwell for 4 h. The reactionwas
stopped by addition of dimethyl sulfoxide (DMSO). Optical density
was measured at 570 nm (and 670 nm for background) in a multi
well plate reader (model 3550; Bio-Rad). Background absorbance of
the medium in the absence of cells was subtracted. In this study,
samples were treated in triplicate, and the mean for each experi-
ment was calculated. Results were considered as a percentage of
the untreated control, which was deﬁned as 100%. Experiments
were repeated at least three times and the mean IC50 value
Fig. 2. Piggybac-based gene delivery generates stable transfectants derived from hADSCs and B16F10. A) Untranfected hADSCs, B) Transfected hADSCs containing EGFP, C)
Untranfected B16F10, D) Transfected B16F10 containing RFP (tdTomato). Bar¼ 100 mm.
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2.9. In vivo studies
Eight-week-old female C57BL/6 mice were purchased from the
Pasteur institute of Iran. Maintaining of the animals was done in
accordance with Institutional Animal Care and Use Committee
guidelines. Each group included 20 mice (10 mice for laboratories
tests and 10 mice for survival), and the experiment was repeated
twice. For establishing lung metastasis, 3 105 B16F10 cells were
injected by tail vein into each mouse. After 10 days, tumors
established in the lungs and mice were tail vein injected with
1 106 cells of three different hADSCs groups: unmodiﬁed hADSCs,
hADSCs-mock and hADSCs expressing IP-10. To conﬁrm the
establishment of tumors in the lungs we used transfected REF-
B16F10 and to track hADSCs we used hADSCs-EGFP (the main
vector composed of IP-10 þ EGFP).
Mice were euthanized at different time points; tissue samples
were harvested, and were made parafﬁn sections from each sam-
ple. Tissue sections were dewaxed by xylene and rehydrated in
graded alcohol. Endogenous peroxidase activity was blocked with
0.3% (vol/vol) hydrogen peroxide in methanol before the slides
were washed in water. Slides were incubated in citrate buffer (pH
6.0) for 20min in a steamer for antigen retrieval for anti-CD31, anti-
CD137, and anti-Foxp3. Nonspeciﬁc binding was blocked by incu-
bating the slides in 5% (vol/vol) in normal serum (depending on the
animal in which the secondary antibody was raised). The following
primary antibodies, at the following dilutions, were used: anti-
CD31, 1:50 dilution (catalog no. ab28364, Abcam; Cambridge,
MA); anti-CD137 polyclonal antibody, 1:600 dilution (catalog no.
ab203391, Abcam; Cambridge, MA); and antibody for anti-F0xp3,
1:100 dilution (catalog no. ab54501; Abcam, Cambridge, MA). Af-
ter binding primary antibodies, slides were incubated with the
respective secondary antibodies conjugated to horseradish perox-
idase, 1:1000 dilution (catalog no. ab97200; Abcam, Cambridge,
MA). The bound antibody was visualized by the peroxidase-based
Vectastain Elite ABC Kit (Vector Laboratories, Peterborough, UK).The substrate reaction was stopped by washing the slides in
running water. Finally, the slides were lightly counterstained with
hematoxylin. To investigate the cell apoptosis, the tissue sections
were treated with the DAB (3, 3-diaminobezidine tetrahydro-
chloride) (Roche Applied Science, Mannheim, Germany) substrate
solution for color development in a dark chamber at room tem-
perature for 10min. After dehydration of tissue sections in ethanol,
they were cleared by xylene, and mounted by DPX (Shandon,
Thermo scientiﬁc, USA). Finally, tissue sections were evaluated by
ﬂuorescent microscope under100 eyepiece magniﬁcation in each
sample. To determine total number of cells and the number that
stained positive in each ﬁeld, 10 randomly chosen ﬁelds were
counted [12].
2.10. Enzyme-linked immunosorbent assay
Blood was collected from mice at different time points (before
and after treatment), and serumwas maintained frozen at 80 C. To
quantitate the amount of IP-10 protein, serum was applied in
triplicate in an enzyme-linked immunosorbent assay (ELISA) spe-
ciﬁc for mouse IP-10 (catalog no. ab9938; Abcam, Cambridge, MA)
according to the manufacturer's protocol and analyzed at an
absorbance of 450 nm.
2.11. Western blotting on mouse tissues
Western blotting was applied to investigate in vivo apoptosis
and homing of hADSCs in 10 samples of fresh lung tissue in various
groups. A measured amount of proteins were separated by SDS-
PAGE and transferred to membranes. The membranes were
blocked with 5% non-fat dry milk in TBST buffer for 2 h at room
temperature, treated with anti-caspase 8 antibody (catalog no.
9746; Cell Signaling, USA), 1:1000 dilution overnight at 4 C,
washed in TBST, and treated again with horseradish peroxidase-
conjugated secondary antibody 1:1000 dilution (catalog no.
ab37168; Abcam, Cambridge, MA) for 2 h at room temperature.
Enhanced chemiluminescence was used to determine protein
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group. The time to reach end point (TTE) for each mouse was
assessed based on the equation of the line reached by exponential
regression of the tumor growth curve. The percent of tumor growth
delay (%TGD) was obtained from the equation %TGD ¼ (T - C)/
C 100 based on the difference between the mean TTE of various
group (T) and the mean TTE of the control group (C) [19]. Increase
life span (%ILS) for each group was assessed based on the following
equation: (mean survival time of each group/mean survival time of
control group 100) - 100 [20].
2.12. Terminal deoxynucleotidyl transferase-mediated dUTP nick-
end labeling (TUNEL) assay
To assess apoptosis, we used TUNEL assay. Samples were pre-
pared as described above [21]. At ﬁrst, tissue samples from lung
were ﬁxed in 10% neutral buffered formalin solution, and
embedded in parafﬁn. The presence of apoptotic cells within the
tissue samples was performed using the in situ cell death detection
kit (Fluorescein; Roche) following the manufacturer's instructions.
It is based on the enzymatic addition of digoxigenin nucleotide to
the nicked DNA by terminal deoxynucleotidyl transferase. In the
tissue sections, ten equal-sized ﬁelds were randomly chosen and
analyzed.
2.13. Statistical analysis
Statistical analysis was done using SPSS version 19 (SPSS Inc,
Chicago, IL). The statistical differences between the groups were
performed by Student t-test, ANOVA, and log-rank tests. Survival
was deﬁned as the date of melanoma cell injection to the date of
death. P values less than 0.05 were considered statistically
signiﬁcant.
3. Results
3.1. Expression of EGFP and RFP in hADSCs and B16F10
Characterization of hADSCs was done in our previous study [17].
To evaluate the efﬁciency of the Piggybac system in generating
stable transfectants, hADSCs and B16F10 cells were transfected
with one and three vectors, respectively, and transfection efﬁciency
was assessed using ﬂuorescent microscope 72 h after transfection.
Our results indicated that transfection rate in hADSCs and
B16F10 cells were 95e100% (Fig. 2). Transfection rates were deter-
mined by counting the number of hADSCs containing EGFP and
B16F10 containing tdTomato in 10 randomly chosen areas of cell
culture. Moreover, we obtained stable clones of transfection cells
through treating hADSCs and B16f10 cells with hygromycin B and
neomycin for at least 14 days respectively.
3.2. High level expression and bioactivity of piggybac encoding IP-
10
High expression of the transgenic mRNA and protein was
conﬁrmed using RT-PCR and Western blot analyses, respectively.
hADSCs were transfected with either mock or PB-IP-10. Fig. 3A and
B shows a strong band of IP-10 in the PB-IP-10 group but not in the
control group (mock), which conﬁrmed high-level expression of
the transgenic protein at the expected molecular weight of 8.7 kDa
[22].
To determine the bioactivity of PB-IP-10 transgene protein,
hADSCs were either transfected with mock or PB-IP-10. One week
later, supernatants were harvested and concentrated. IP-10 con-
centration in the supernatant was assessed using ELISA and foundto be 2.4 ng/mL. To investigate the effects of IP-10 on cell prolifer-
ation, MTTassaywas performed in B16F10 cells. The results showed
signiﬁcant inhibition of tumor growth with 100 ml of supernatant
from hADSCs transfected with PB-IP-10 (p ˂0.001; Fig. 3C).
3.3. MSC homing to tumors in the lung and expressing IP-10
To determine tumor establishing in the lungs, we used B16F10
transfected with PBe tdTomato (RFP). After 10 days, tumors were
established in the lungs. To assess the homing of transplanted
hADSCs to tumor sites in the lungs, we injected hADSCs-IP-10
which also expressed EGFP. The modiﬁed B16F10 and hADSCs
were intravenously injected to mice. Ten days after the adminis-
tration of hADSCs, the mice were sacriﬁced and tissues were har-
vested. Microscopic and western blot analysis of mice lung
provided evidence that tumors had manifested in lungs and hom-
ing of hADSCs to the tumor site in the lungs as shown in Fig. 4.
Systemic expression of IP-10 in mice that received hADSC was also
conﬁrmed by ELISA on serum of mice in speciﬁc time points. Our
results indicated that there was no signiﬁcant increase in the level
of IP-10 after treatment in the hADSCs expressing IP-10 group than
other groups ((*, p ˂0.05) (Fig. 4D).
3.4. Antitumor effects of hADSCs transfected with a PB-IP-10
One hundred C57BL/6 mice divided in ﬁve groups (20 mice per
group) and 3 105 B16F10 cells were injected by tail vain. After ten
days, mice were received no treatment or hADSCs (1 106) that
were without vector or with mock or PB-IP-10. Twenty day later,
ten mice in each group were sacriﬁced to assessing the effect of
therapy, and the remaining mice (n¼ 10) were considered for long-
term survival (Fig. 5). Our results indicated that treatment of
B16F10 bearing mice with hADSCs expressing IP-10 could signiﬁ-
cantly decrease metastatic colonies in the lungs (p ˂0.001)(Fig. 5 A,
B, Table 1). There was no signiﬁcant therapeutic effect observed in
other groups (Fig. 5B). hADSCs expressing IP-10 were observed to
signiﬁcantly increase the survival of mice. Whereas all animals in
control group died by day 30, more than 80% of mice given hADSCs
expressing IP-10 survived beyond that time (p˂ 0.01)(Fig. 5C). Sur-
vival of 30% mice in hADSC-IP-10 group was found up to 70 days.
Table 1 provided some key indicators which are associated with
therapeutic efﬁcacy on various groups including median survival
time (MST), time to reach end point (TTE), tumor growth delay (%
TGD), and increase life span (%ILS) for each treatment group in
mouse model. The hADSC-IP-10 group signiﬁcantly increased the
MST, TTE, TGD and ILS compared to all the other groups. However,
there were no signiﬁcant differences among No treatment group
(B16F10), control PBS, hADSC, hADSCs þ Mock.
3.5. Effects of hADSCs eIP-10 on apoptosis, and angiogenesis
Results of immunohistochemistry, TUNEL assay, Western blot-
ting and the quantitative analysis showed a signiﬁcant decrease in
tumor vasculature (p ˂0.01) and an increase in apoptosis (p ˂ 0.01)
following treatment with hADSCs producing IP-10 compared with
untreated animals. No such a difference versus control group was
seen in tumors of mice treated with other groups which suggested
that the effects were due to IP-10 (Fig. 6).
3.6. Effects of hADSCs transfected with a PB-IP-10 on immune cells
(activated T cells and Tregs)
We have assessed the activation and inﬁltration of T cells and
Tregs in the lung after injection of hADSCs-IP-10 compared with
hADSCs, hADSCs-mock, and PBS groups (Fig. 7). Results of
Fig. 3. Expression of IP-10 in hADSCs was analyzed by RT-PCR (A) and Western blot (B) following transfection with PB- IP-10 or mock. The effect of PB- IP-10 on cell proliferation is
shown in (C). The bioactivity of PB-IP-10 was determined in vitro in B16F10 cells by incubating the cells in conditioned media obtained from hADSC cultures which were either
transfected, mock or PB-IP-10 (**, p ˂0.001). Error bars represents (e.g. standard deviation).
H. Mirzaei et al. / Cancer Letters 419 (2018) 30e39 35immunohistochemistry and Quantitative analysis indicated that
there are signiﬁcant difference in population of activated T cells and
Tregs between hADSCs-IP-10 and other groups respectively (***, p
˂0.001).4. Discussion
For many years, the cornerstones of cancer therapy has been
surgery, chemotherapy and radiotherapy [23]. Over the last decade,
targeted therapies have emerged as promising treatments for
various types of cancer. Furthermore, current limitations in the
conventional therapies for solid and metastatic tumors such as
systemic toxic side effects and insufﬁcient accumulation of thera-
peutic agents in the tumor sites preclude achieving complete
remission in most patients [23]. Therefore, there is a need to ﬁnd
alternative treatments that can circumvent the challenges posed by
the current conventional anticancer therapies. One approach for
cell based-cancer therapy involves the use of genetically-
engineered MSCs [24,25]. Tumor microenvironment provides a
preferential niche for MSCs homing to tumor sites. As such,
inherent tumor-tropic properties of MSCs makes them appealing
candidates for targeted delivery of anticancer agents [24,26,27].
One of the chemoattractant cytokine with pleiotropic antitumor
effects is IP-10 [4]. IP-10 displays several anticancer effects
including induction of tumor cell necrosis, generation of effector T
cells, attraction of T cells, monocytes, neutrophils, and possibly NK
cells to tumor sites, restriction of tumor angiogenesis and inhibition
of metastasis [4]. In this regards, it seems that generation of
genetically-modiﬁed MSCs producing IP-10 has a great therapeuticpotential in the treatment of cancers particularly metastatic tu-
mors. In the current study, we evaluated the antitumor activity of
IP-10-producing hADSCs in an immunocompetent mouse model of
metastatic melanoma. Our results indicated that hADSCs were able
to deliver IP-10 to primary and metastatic tumor sites in vivo.
Several studies have demonstrated that injection of autologous
ex vivo-expanded MSCs alone or in combination with various
therapeutic agents is associated with relatively benign adverse ef-
fects in cancer patients [13,14,28e31]. We found that there was no
speciﬁc immune response against the injected cells, explaining not
only the prolonged survival of MSC in our model but also the
immunomodulating effect of our therapeutic strategy. In agree-
ment with our ﬁndings, previous studies showed that allogeneic
MSCs did not elicit speciﬁc cellular immune response against the
transplanted cells [32e34]. Grisendi et al. demonstrated that
hADSCs producing tumor necrosis factorerelated apoptosis-
inducing ligand (TRAIL) engrafted into tumors mediated
apoptosis without a signiﬁcant toxicity to normal tissues. They
concluded that transgenic hADSCs could be used as safe cellular
therapeutic vehicles for cancer therapy [16]. In another study, we
used hADSCs producing IFNg in an immunocompetent mouse
model of metastatic melanoma [15]. Our in vivo results showed that
IFNg-expressing ADSCs, localized into tumor stroma, inhibited tu-
mor growth and angiogenesis, hindered systemic increase of Tregs,
enhanced expression of PD-L1 and inﬁltration of CD8þ cells (but not
interleukin-2þ cells), and prolonged the survival of mice [15].
In the current study, we showed that there was no signiﬁcant
increase in the serum level of IP-10. A large number of studies have
indicated that elevated serum levels of various cytokines are
Fig. 4. Tumor establish and homing of hADSC in mice lungs. Microscopic analysis of establishing B16F10 in lungs and the homing of hADSCs expressing IP-10 in tumor sites in lungs,
conﬁrmation of expression of IP-10 in lungs and systemic IP-10 levels before and after treatment. C57BL/6 mice bearing B16F10 -tdTomato tumors (n¼ 20) in the lungs were injected
with 1 106 hADSCs expressing IP-10. Tumor establishment was deﬁned 6 days after injection and homing of hADSCs expressed IP-10 were deﬁned in ten days after treatment by
microscopic (A,B) and western blot analysis (C). Twenty days after injection, mice were sacriﬁced, lungs were harvested, and samples were provided for Western blotting (C). An
ELISA for IP-10 levels was done in triplicate with serum samples from mice in before and after treatment with hADSCs (D). Error bars represents (e.g. standard deviation).
Fig. 5. In vivo experiment. C57BL/6 mice were injected with 3 105 B16F10 cells by tail vein injection. After ten days, mice were treated with hADSCs (1 106 cells). Mice were
divided into ﬁve groups (each group 20 mice), which included no treatment, PBS, hADSCs, hADSCs-mock and hADSCs-IP-10. Ten mice of each group were sacriﬁced at day 20 to
determine the effect of therapy, and the remaining mice (n¼ 10) were allowed long-term survival. The in vivo experiment was repeated twice. Images represent a part of lungs from
the indicated treatment groups on day 20 (A) and the number of metastatic colonies (**, p ˂0.01) (B). Survival index is shown in (C) (**, P¼ .0366). Error bars represents (e.g. standard
deviation).
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Table 1
Therapeutic efﬁcacy data of various treated groups in mice bearing B16F10 meta-
static lung tumor.
Group MST (day) TTE (days± SD) TGD (%) ILS
B16F10 23 20.42± 1.56 e
PBS 26 20.57± 2.85 0.73 13.04
hADSC 26 20.42± 1.26 e e
hADSC þ Mock 24 21.42± 4.31 4.89 4.34
hADSC-IP-10 50 47± 3.22 130.16 117.39
MST:Median survival time, TTE: Time to reach end point, TGD: Tumor growth delay,
ILS: Increase life span.
H. Mirzaei et al. / Cancer Letters 419 (2018) 30e39 37associated with systemic adverse effects in patients. Therefore, it
seems that employing hADSCs for delivering IP-10 to the tumor
sites without signiﬁcant increase in plasma cytokine level would
prevent undesirable systemic adverse effect. According to our re-
sults, hADSCs expressing IP-10 are able to restrict the anti-cancer
activity of IP-10 to tumor sites without evidence of systemic
adverse effects. These results suggest that hADSCs could be used as
effective vehicles for targeting therapeutic agents.
It has been shown that IP-10 can induce apoptosis in cancer
cells. Our results indicated that hADSCs expressing IP-10 signiﬁ-
cantly increased apoptosis rate in melanoma cells. Western blotting
for caspase 8 indicated that IP-10 exerts its pro-apoptotic effectsFig. 6. TUNEL assay, western blotting, and immunochemistry of lungs with B16F10 tumors
tumor cell apoptosis, and microvessel density, lungs were parafﬁn-embedded and sectioned.
days and ﬂuorescence images were visualized under an Axio vision 4.0 ﬂuorescence microsc
cells in 10 random ﬁelds (**, p˂0.01) (B). Ten days after treatment, lungs were harvested, and
with anti-CD31 polyclonal antibody for endothelial cells (D). Blood vessel counts were deter
sections (**, p ˂0.01) (E). Error bars represents (e.g. standard deviation).likely via targeting caspase 8. Sahin et al. showed that CXCL10
mediated the apoptosis of hepatocytes through TLR4 signaling, a
non-cognate chemokine pathway. Therefore, CXCL10 speciﬁcally
induces prolonged protein kinase B and Jun N-terminal kinase
activation, leading to hepatocyte apoptosis by caspase-8, caspase-3,
and p21-activated kinase 2 (PAK-2) cleavage [35]. It has been
exhibited that caspase-8 is an upstream caspase and could cleave
its downstreammolecules such as caspase-3 and PAK-2 in response
to IP-10 [35,36].
Inhibition of angiogenesis is another important effect of IP-10
which contributes to tumor regression in various cancers such as
melanoma. We showed that IP-10 is able to signiﬁcantly decrease
angiogenesis and vessel density in themetastatic lung tissue. Yates-
Binder et al. demonstrated that utilization of an IP-10-derived
peptide (IP-10p) signiﬁcantly inhibited tube formation and VEGF-
induced endothelial motility in vitro, the properties crucial for
angiogenesis [37]. Moreover, an in vivo study showed that IP-10p is
able to reduce both vessel formation and induced involution of
nascent vessels through increasing cAMP production, activation of
PKA and, thereby, inhibiting cell migration and VEGF-mediated m-
calpain activation [37].
We showed that IP-10 increased the number of activated T cells
but decreased Treg cells in the tumor tissue. Through interacting
with tumor cells and tumor-associated stroma, T cells and Tregs arefor assessing apoptosis, and angiogenesis. For immunochemical and TUNEL analysis of
TUNEL assay was carried out in lungs sections treated with or without therapy after 10
ope (A). Quantitative analysis of apoptotic indices were calculated by counting positive
samples were provided for Western blotting for Caspase 8 (C). Staining was performed
mined by counting the number of vessels in 10 randomly chosen areas of CD31 stained
Fig. 7. Determination of immune cells (activated T cells and Tregs) in the lung following IP-10 therapy. All administrations were injected intravenously into C57BL/6 mice with lung
metastases of B16F10 cells (n¼ 20 in each group). Twenty days later, lung was harvested; frozen sections were made the tissue for immunohistochemistry. Staining was done with
rat polyclonal antibody speciﬁc for mouse CD137, and FOXP3. Slides were minimally counterstained with hematoxylin (A, C). Quantitative analysis of activated T cells and Tregs were
calculated by counting the number of cells in 10 randomly chosen areas of CD137 and FOXP3 stained sections respectively (***, p ˂0.01) ((B, D). Error bars represents (e.g. standard
deviation).
H. Mirzaei et al. / Cancer Letters 419 (2018) 30e3938key players in determining antitumor immune responses. Several
studies have indicated that IP-10, either as combination therapy or
stand-alone therapy, exerts its anti-tumor effects through multiple
immunomodulatory mechanisms such as recruiting immature
antigen-presenting cells or early activated T cells to the tumor site,
promoting a strong CTL response, and suppressing Treg accumu-
lation in experimental animal models [6,38,39]. It has also been
shown that IP-10 can cause tumor necrosis and vascular damage at
the tumor site without provoking a substantial inﬂammatory
response [40]. Migration of T cells to the tumor site could enhance
the therapeutic efﬁcacy of the antitumor immune response.
Sharma et al. demonstrated that some cytokines and chemokines
including IFN-g, CXCL9 and IP-10 exert their anti-tumor effects
through increasing T cell populations (both CD4þ and CD8þ) [7].
Dufour and colleagues reported that IP-10 can enhance generation
and trafﬁcking of activated T cells. In their study, IP-10 knockout
(KO) mice showed a decreased recruitment of CD4þ and CD8þ
lymphocytes accompanied by low levels of IFN-g,CXCL9 and
CXCL10 in the brain tissue.
Treg cells and their associated cytokines such as IL-10 and TGF-b
may play a role in promoting tumor growth and progress by
inhibiting the immune response against tumor. It has been shown
that the number of Treg cells is inversely correlated with antitumor
response of CD8þ T cells and patients' survival [41e44]. In contrast
to our results, various studies have revealed that tumor-derived IP-
10 attracts Tregs to the tumor sites and thereby promotes immu-
nosuppression and tumor progression. These studies suggestedthat IP-10 expression is correlated with Tregs inﬁltration and poor
survival [45]-47). The dual effects of IP-10 (anti-tumor vs. tumori-
genic effects) seem to be due to spliced variants of the corre-
sponding CXCR3 receptor. It has been shown that CXCR3-B has
growth-inhibitory effects, whereas CXCR3-A could induce cell
proliferation (48).
In summary, our results demonstrated that hADSC-mediated
delivery of IP-10 could induce apoptosis, increase trafﬁcking of
activated T cells to the tumor site, restrict angiogenesis, and hinder
accumulation of Tregs in mice bearing melanoma lung metastasis.
Moreover, our in vivo data indicated that employing hADSCs pro-
ducing IP-10 could prolong survival of mice bearing B16F10 lung
metastasis tumors. These ﬁndings suggest that hADSC-based tar-
geted delivery of therapeutic agents such as IP-10 could be regar-
ded as a novel and effective therapeutic strategy for inhibition of
tumor growth and targeting tumor metastasis.5. Acknowledgments
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